A Comparison of Professional Traders and Psychopaths in a Simulated Non-Zero Sum Game

In a prior study psychopathic individuals showed a diminished level of cooperativeness but realized higher individual rewards in a prisoner’s dilemma game, compared with community controls. The present study replicated this finding with professional bank traders, who exhibited less cooperative behavior than both of the aforermentioned groups (community controls and psychopathic patients). While the bank traders did not obtain a higher gain than the psychopathic individuals at an absolute level, they maximized the discrepancy between their own profit and the yield of their anonymous computerized gaming partner. The bank traders were more prone than psychopathic patients to rely on strategies that considerably harmed the profit of their gaming partners without necessarily optimizing their own total profit. The community controls achieved the same overall gain as traders and psychopaths. Unlike traders and psychopathic patients, the normal controls balanced overall gains of themselves and their game opponent, which led to the highest overall profit, whereas the traders achieved the lowest overall profit

PharmaSUG 2015 -Paper QT33

ABSTRACT In Pharmaceuticals/CRO industries, table programing is often started when only partial data is available and it is common that we need to summarize data based on all possible combinations of values. However, if there is no data collected for all levels of these values in the data set, by default, existing SAS procedures are not able to display them in a summary table. A viable solution is to add the PRELOADFMT option in these procedures. PROC FREQ is commonly used procedure to summarize data and calculate statistics, but the PRELOADFMT option is not supported. However using the existing SAS procedures (e.g. PROC FORMAT, PROC DATASETS, and PROC FREQ), we can create a SAS macro which can perform the above mentioned task easily without much programming work

Workshop On Reduction Of Demand For Illicit Drugs In South-East Asia.

The member Governments of the COLOMBO PLAN BUREAU, recognizing the increasing level of demand for illicit drugs - especially narcotic drugs in the South-East Asian region, and the problems associated with the assessment treatment and rehabilitation of those persons dependent on drugs suggested that the Drug Advisory Programme of the COLOMBO PLAN BUREAU investigate the feasibility of organising a regional workshop in this field

International Monograph Series 11: Report Of The Asian Multicity Epidemology Workgroup 1997.

The Asian Multi-City Epidemiology Study Program has entered its fifth year in 1997

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.

We evaluated homologous recombination deficient (HRD) phenotypes in epithelial ovarian cancer (EOC) considering BRCA1, BRCA2, and RAD51C in a large well-annotated patient set. We evaluated EOC patients for germline deleterious mutations (n = 899), somatic mutations (n = 279) and epigenetic alterations (n = 482) in these genes using NGS and genome-wide methylation arrays. Deleterious germline mutations were identified in 32 (3.6%) patients for BRCA1, in 28 (3.1%) for BRCA2 and in 26 (2.9%) for RAD51C. Ten somatically sequenced patients had deleterious alterations, six (2.1%) in BRCA1 and four (1.4%) in BRCA2. Fifty two patients (10.8%) had methylated BRCA1 or RAD51C. HRD patients with germline or somatic alterations in any gene were more likely to be high grade serous, have an earlier diagnosis age and have ovarian and/or breast cancer family history. The HRD phenotype was most common in high grade serous EOC. Identification of EOC patients with an HRD phenotype may help tailor specific therapies.This work was supported by National Institutes of Health grants R01-CA122443, P50-CA136393, P30-CA15083, and the Fred C. and Katherine B. Andersen Foundation. We thank Gary Kenney, M.D. for pathology review of tumor tissue. We thank Craig Luccarini, Caroline Baynes from University of Cambridge for assisting our sample sequencing